Episode

395: Biotech investors' plea to Trump, and a busy M&A week

Podcast
The Readout Loud
Published
Apr 2, 2026
Duration seconds
1918
Processing state
not_requested
Canonical source
https://traffic.megaphone.fm/TTSAA6976080442.mp3?updated=1775158295
Audio
https://traffic.megaphone.fm/TTSAA6976080442.mp3?updated=1775158295
JSON
/v1/public/podcasts/the-readout-loud-1134305/episodes/395-biotech-investors-plea-to-trump-and-a-busy-m-a-week
Markdown
/podcast/the-readout-loud-1134305/395-biotech-investors-plea-to-trump-and-a-busy-m-a-week.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-readout-loud-1134305/episodes/395-biotech-investors-plea-to-trump-and-a-busy-m-a-week/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-readout-loud-1134305/395-biotech-investors-plea-to-trump-and-a-busy-m-a-week.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

How has the Food and Drug Administration's recent decisions on rare disease drugs affected investment trends? Why is Eli Lilly getting into sleep medicine? And where did Allison go on her vacation? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's weekly biotech podcast. Biotech investor Rod Wong joins us to talk about why an industry-patient coalition he's part of sent a letter to President Trump asking for more regulatory flexibility at the FDA. We also discuss the U.S. approval of Eli Lilly's obesity pill, recent deal-making by large pharma companies, a strange story about promotion of psychedelic drugs on YouTube, and more.